On November 26, the Biden administration made a groundbreaking announcement that Medicare and Medicaid would soon cover weight loss medications like Ozempic and Wegovy, aimed at addressing obesity. This plan is set to provide access to these crucial medications for over seven million people in the United States who rely on Medicare and Medicaid, as reported by NBC News.

While this decision has sparked excitement among those who have experienced significant weight loss using semaglutides, it has also raised eyebrows regarding its potential impact on public health and the economy. We consulted with healthcare professionals and patients to debunk common myths surrounding semaglutides.

1. It's Just a Quick Fix

Dr. Addy, a weight loss specialist from Texas, emphasizes that success with these medications is tied to patient commitment. “Those who see tangible results are often engaged in lifestyle changes—adopting better diets, ensuring sufficient fiber intake, and incorporating regular exercise,” she explains. These medications are tools to aid a broader health strategy, not standalone solutions.

2. There Are Too Many Side Effects

The fear of side effects can deter potential users. However, many experts, including @DrWellRx, note that while side effects such as nausea and constipation are common, they are generally mild and manageable. Furthermore, a recent study in JAMA Network Open revealed that patients taking medications like Wegovy and Mounjaro reported positive lifestyle changes, including reduced alcohol consumption, which can enhance weight loss efforts. TikTok user @blisswithbri corroborates this by sharing that her cravings for nightly wine have decreased significantly, supporting her weight loss journey.

3. Medications Are Being Taken from Diabetics

A prevalent concern is that patients aiming for weight loss are depriving diabetics of essential medications. Holistic obesity expert @Dr_JonesDC clarifies that this depends on the source of the medication. If patients obtain semaglutide from a retail pharmacy, they could be impacting access for diabetics. However, using a compounding pharmacy for personalized medications does not diminish availability for diabetic patients.

4. The Cost to Taxpayers Will Be High

Critics often argue against the financial implications of broader access to these drugs. However, Dr. Jon LaPook, Chief Medical Correspondent for CBS News, asserts that the long-term health benefits gained from these medications could outweigh immediate costs. “Medications like these can significantly reduce risks associated with obesity—think heart disease, stroke, and diabetes,” he says. The invaluable return on investment in health cannot simply be measured in dollar signs.

5. Weight Gain is Inevitable After Stopping Medication

Many worry that discontinuing semaglutides will lead to rapid weight regain. Dr. Yoni Freedhoff, a recognized authority in family medicine, argues that ceasing any effective treatment could result in a return to previous health issues. However, nuanced views exist, as pointed out by nurse practitioner @medically.bl0nde. Maintaining lifestyle modifications could allow some individuals to sustain their weight loss. Conversely, those with underlying metabolic conditions might struggle to retain their progress without ongoing support.

As the landscape around weight management evolves with advancements in medications like Ozempic and Wegovy, staying informed about the facts—and myths—will empower individuals to make better health decisions. Ultimately, the responsibility for health improvement remains a shared effort between medical professionals, policymakers, and patients themselves.